Results 51 to 60 of about 2,175,372 (155)

Characterization of cisplatin effects in lenvatinib‐resistant hepatocellular carcinoma cells [PDF]

, 2022
香川大学Kagawa University博士（医学）Background/aim: Drug resistance to molecular targeted agents, such as lenvatinib, is an important issue. The aim of this study was to explore the mechanism of lenvatinib resistance and to investigate potential drugs that may ...
濱谷, 紗江, Hamaya, Sae, ハマヤ, サエ   +2 more
core   +2 more sources

Targeting Macrophage‐Mediated Lymphatic Immunosuppression to Prevent Tumor Recurrence After Microwave Ablation

Advanced Science, EarlyView.
Incomplete microwave ablation induces animmunosuppressive microenvironment in tumor‐draining lymph nodes. An albumin‐based lipoprotein nanosystem enables coordinated delivery of immunomodulators to tumor‐draining lymph nodes and residual tumors, reverses post‐ablation immunosuppression, suppresses residual tumor growth, and promotes durable antitumor ...
Xuexia Shan, Yuting Shen, Xiaodong Hou, Fengshan Jin, Shaoyue Li, Weichen Xu, Weiwei Ren, Xiaowan Bo, Qiuyan Li, Shuo Liu, Weifan Hao, Chengzhong Peng, Huixiong Xu, Liping Sun, Wenwen Yue   +14 more
wiley   +1 more source

Supplementary Data from Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3–ABCB1 Signaling in Hepatocellular Carcinoma

, 2022
Supplementary Data from Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3–ABCB1 Signaling in Hepatocellular ...
Xufeng Wang (14958272), Tiantian Zou (14958233), Yan Zheng (14958254), Tian-En Li (14958263), Chao-Qun Wang (14958257), Xudong Ren (14958278), Wei Qin (10919477), Xiaotian Shen (14958236), Shun Wang (14958266), Yang Chen (14958245), Lun-Xiu Qin (14958284), Haoting Sun (14958251), Beiyuan Hu (14958230), Le Zhu (14958269), Zhengxin Wang (14958260), Yinghan Su (14958239), Jianhua Li (14958242), Yan Fu (14958275), Ze Zhang (14958248), Qiongzhu Dong (14958281)   +19 more
core   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Phthalates promote lenvatinib resistance in hepatocellular carcinoma through the HPX-MAPK pathway

Ecotoxicology and Environmental Safety
Lenvatinib resistance is a major obstacle in the treatment of hepatocellular carcinoma (HCC). Phthalates, widespread environmental plasticizers, may contribute to therapeutic resistance, yet their impact on HCC remains unclear.
Jinlu Han, Chen Wang, Yun Song, Hong Hu, Mengyan Chen, De Zhao, Qiong Wu, Ling Xu   +7 more
doaj   +1 more source

Advanced In Vitro Platforms for Experimental Liver Research: From Organoids and Liver‐on‐Chip to Omics and Artificial Intelligence

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Hepatocytes perform essential physiological functions in the human body. Gaining more profound insight into the liver structure, diseases, and physiology by using in vitro models can help to propose more relevant clinical applications. Conventional in vitro liver models, such as two‐dimensional (2D) cell cultures, fail to adequately replicate ...
Seyedeh Kiana Teymorian, Pedram Asadi Sarabi, Abbas Piryaei, Massoud Vosough   +3 more
wiley   +1 more source

From pathogen to “living drug factory” innovative strategies and clinical translation of bacteria as programmable intelligent vectors for cancer therapy

BMEMat, EarlyView.
Engineered bacteria serve as smart, living therapeutics that target tumors, deliver drugs, and remodel immunosuppressive microenvironments. This review highlights their potential to potentiate immunotherapy, radiotherapy, and chemotherapy, offering a promising paradigm for precise and synergistic cancer treatment. Abstract The dynamic interplay between
Haonan Shen, Weichen Zhang, Gaoli Niu, Li Wang, Ruiyan Li, Yueyue Fan, Feixue Lu, Lingling Xu, Xiaoyuan Ji, Yong Kang   +9 more
wiley   +1 more source

The p-MYH9/USP22/HIF-1α axis promotes lenvatinib resistance and cancer stemness in hepatocellular carcinoma. [PDF]

Signal Transduct Target Ther
Lenvatinib is a targeted drug used for first-line treatment of hepatocellular carcinoma (HCC). A deeper insight into the resistance mechanism of HCC against lenvatinib is urgently needed.
Shan Q, Yin L, Zhan Q, Yu J, Pan S, Zhuo J, Zhou W, Bao J, Zhang L, Hong J, Xiang J, Que Q, Chen K, Xu S, Wang J, Zhu Y, He B, Wu J, Xie H, Zheng S, Feng T, Ling S, Xu X.   +22 more
europepmc   +2 more sources

Lenvatinib rechallenge in a patient with advanced thymic carcinoma: A case report

Thoracic Cancer, 2022
Advanced thymic carcinomas have limited treatment options. Recently, lenvatinib was approved for advanced thymic carcinoma treatment. However, the clinical benefit of lenvatinib re‐administration in patients with advanced thymic carcinoma who developed ...
Yuto Terashima, Taiki Hakozaki, Susumu Takeuchi, Yukio Hosomi   +3 more
doaj   +1 more source

ATP Citrate Lyase in Metabolic Disease: Mechanistic Insights and Clinical Potential

iNew Medicine, EarlyView.
ATP citrate lyase (ACLY) is a central metabolic hub that diverts mitochondrial citrate to fuel de novo lipogenesis, cholesterol biosynthesis, and protein acetylation. Given its robust correlation with pathological changes in multiple human diseases, ACLY inhibitors featuring distinct pharmacological strengths have been developed for therapeutic ...
Wenbiao Wang, Xinyan Li, Honglu Shi, Gaolei Song, Zhifu Xie, Jingya Li   +5 more
wiley   +1 more source